Spectranetics Corp  

(Public, NASDAQ:SPNC)   Watch this stock  
Find more results for Kimberly McIntosh
-0.03 (-0.18%)
Real-time:   1:15PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.33 - 16.59
52 week 14.77 - 37.04
Open 16.43
Vol / Avg. 173,080.00/1.31M
Mkt cap 696.97M
P/E     -
Div/yield     -
EPS -1.50
Shares 42.45M
Beta 0.97
Inst. own 111%
Oct 21, 2015
Q3 2015 Spectranetics Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Aug 12, 2015
Spectranetics Corp at Canaccord Genuity Growth Conference - Webcast
Jul 23, 2015
Q2 2015 Spectranetics Corp Earnings Call - Webcast
Jul 23, 2015
Q2 2015 Spectranetics Corp Earnings Release
Jun 12, 2015
Spectranetics Corp Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -11.70% -19.96%
Operating margin -8.53% -18.03%
EBITD margin - 0.63%
Return on average assets -6.48% -11.96%
Return on average equity -20.97% -23.23%
Employees 753 -
CDP Score - -


9965 Federal Dr
United States - Map
+1-719-6338333 (Phone)
+1-877-4472022 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. The Company offers excimer laser system known as the CVX-300. Its Vascular Intervention business unit includes a range of peripheral and cardiac laser catheters for ablation of blockages in arteries above and below the knee (peripheral atherectomy) and within coronary arteries (coronary atherectomy); support catheters to facilitate crossing of coronary and peripheral arterial blockages (crossing solutions); and thrombectomy catheters for the removal of thrombus (thrombus management). The Company’s Lead Management business unit includes excimer laser sheaths, non-laser sheaths and cardiac lead management accessories.

Officers and directors

R. John Fletcher Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Scott William Drake President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Guy A. Childs Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shahriar Matin Chief Operating Officer
Age: 40
Bio & Compensation  - Reuters
Paul Gardon Senior Vice President, General Counsel
Age: 49
Bio & Compensation  - Reuters
Kimberly McIntosh Bridges Senior Vice President - Sales and Marketing of Vascular Intervention
Age: 41
Bio & Compensation  - Reuters
Donna Ford-Serbu Senior Vice President - Sales and Marketing of Lead Management
Age: 46
Bio & Compensation  - Reuters
Robert Michael Fuchs Senior Vice President, Global Head - Human Resources
Age: 48
Bio & Compensation  - Reuters
Austin B. Byrd Chief Compliance Officer, Vice President
Age: 49
Bio & Compensation  - Reuters
Wade A. Bowe Vice President - Research & Development
Age: 44
Bio & Compensation  - Reuters